UNSPSC 51431507: Tirofiban hydrochloride

This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6H925F8O5J, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, monohydrochloride, monohydrate but more generally known as tirofiban hydrochloride, which bears US NIH Compound Identifier 60946. European Medicines Agency schedules Tirofiban hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04887MIG.

UNSPSC 51431507 Tirofiban hydrochloride, a Commodity code, encompasses advanced cardiac medications supplied to state and local emergency services, public health agencies, and cooperative purchasing alliances. State and local governments buy this and related pharmaceutical products through a mix of direct procurement (typically sealed-bid IFBs for emergency medical services) and cooperative-purchasing frameworks that aggregate demand across multiple jurisdictions and enable manufacturers to supply through licensed wholesalers. The Tampa Fire Rescue procurement exemplifies the direct-buy model: a city contracts for a defined set of Advanced Life Support Medications—including tirofiban and related agents—with firm pricing, expiration guarantees, and rapid delivery windows. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) model, by contrast, establishes master contracts for generic multi-source pharmaceuticals distributed across state and local facilities through three authorized wholesalers, allowing member jurisdictions to draw products as needed under negotiated pricing. Both models require FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) attestation, comprehensive insurance, and Safety Data Sheets; cooperative arrangements add administrative fees (typically 3 percent) and performance penalties for reporting or delivery failures.

Recent activity spans Florida, Minnesota (with participating members including Oregon), and Texas. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications with an estimated contract value of $40,000 and a one-year term plus renewal options, sheltered for Small Local Business Enterprises with a 5 percent bid discount. Minnesota's MMCAP issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products, effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness and 25 percent on administrative compliance, format capability, and fee structure. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in March 2026 to gather vendor capability and market intelligence for a Direct-to-Manufacturer Prescriptions program, an exploratory phase preceding formal solicitation. The code shows active demand from fire rescue departments, state health and human services agencies, and multistate cooperative purchasing vehicles, with sealed-bid and RFP notice types dominating the procurement mechanism.